Lineage Cell Therapeutics, Inc.
LCTX NYSE· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$1.00
KIRA · Stoqly’s AI analyst, in plain words
- Lineage Cell Therapeutics, Inc. had $14.6M of revenue in fiscal 2025, up 53.2% on the year before. Over five years, revenue changed +51.5% a year on average.
- Its operating margin was −251.6%, down 25.5 pts: of every 100 in sales, about −252 is left after running the business.
- Lineage Cell Therapeutics, Inc. lost $63.5M in fiscal 2025.
- Free cash flow was −$19.4M in fiscal 2025, −133.6% of revenue.
Market cap
$261M
P/E
—
Revenue
$14.6M
Net income
−$63.5M
Free cash flow
−$19.4M
Operating margin
−251.6%
Lineage Cell Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+53.2%
Yes. Sales grew 53.2% last year.
Does it make a profit?
−436.5%
No. It lost money last year.
Does profit turn into cash?
−133.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Lineage Cell Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Lineage Cell Therapeutics, Inc.
- CIK
- 0000876343
Lineage Cell Therapeutics, Inc. · LCTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $4.3M | $14.7M | $8.9M | $9.5M | $14.6M |
| Revenue growth | 137.7% | 238.7% | −39.2% | 6.2% | 53.2% |
| Net interest income | $0.0M | $0.8M | — | — | — |
| Gross margin | 67.2% | 95.0% | 92.5% | 96.5% | — |
| Operating margin | −1,133.6% | −153.2% | −276.5% | −226.1% | −251.6% |
| Net income | −$43.0M | −$26.3M | −$21.5M | −$18.6M | −$63.5M |
| Net margin | −991.0% | −178.7% | −240.2% | −195.9% | −436.5% |
| Diluted EPS | −$0.26 | −$0.15 | −$0.12 | −$0.09 | −$0.28 |
| Cash | |||||
| Cash from operations | −$23.6M | $1.1M | −$28.6M | −$23.1M | −$18.9M |
| Capital expenditure | $0.3M | $0.4M | $0.7M | $0.6M | $0.5M |
| Free cash flow | −$23.9M | $0.6M | −$29.2M | −$23.7M | −$19.4M |
| FCF margin | −550.6% | 4.4% | −326.9% | −249.0% | −133.6% |
| Share count change | 9.7% | 103,117.0% | 1.7% | 15.9% | 14.9% |
| Debt and strength | |||||
| Cash and short-term investments | $58.4M | $57.9M | $35.5M | $47.8M | $55.8M |
| Shareholders' equity | $92.2M | $73.3M | $63.4M | $78.4M | $44.5M |
| Current ratio | 2.4x | 3.2x | 2.1x | 3.6x | 5.2x |
| Returns and quality | |||||
| Return on equity | −45.7% | −31.7% | −31.4% | −26.2% | −103.4% |
| Return on tangible equity | −123.9% | −164.5% | −347.4% | −87.9% | −2,918.4% |
| Piotroski F-score | 2 | 6 | 0 | 3 | 3 |
| Altman Z'' | −4.6 | −7.1 | −11.0 | −8.5 | −12.2 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lineage Cell Therapeutics, Inc. · LCTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.00 a share, the company is worth $261M.
Source: SEC EDGAR XBRL filings (CIK 0000876343). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.